<p><strong>Processa Pharmaceuticals</strong>（纳斯达克股票代码：<strong>PCSA</strong>）股价在周二上涨，此前公司发布了美国食品药品监督管理局（FDA）的最新消息。</p>
<p>FDA 已经批准 Processa Pharmaceuticals 进行第二阶段临床试验 Next Generation Capecitabine（NGC-Cap）。这是该公司的主力产品候选药物，旨在治疗晚期或转移性乳腺癌患者。</p>
<p>凭借这一批准，Processa Pharmaceuticals 得以推进 NGC-Cap 的临床试验。该公司表示，他们预计本季度将开始招募参与该研究的患者。</p>
<p>Processa Pharmaceuticals 研发总裁 David Young 对 NGC-Cap 发表了如下看法。</p>
<p>“我们先前在第 1b 阶段研究中证明，NGC-Cap 比单药卡培他滨更有效，使癌细胞暴露于 5-氟尿嘧啶的浓度提高了 5-10 倍。这种更高的暴露导致了更高的疗效，同时安全性优于或类似于现有的单药卡培他滨。”</p>
<h2>今日 PCSA 股票走势</h2>
<p>随着这一消息的传出，PCSA 股票今天交投活跃。截至目前，成交量已超过 5100 万股。与该公司日均成交量约为 9 万股相比，这是一次巨大的涨势。</p>
<p>截至周二上午，PCSA 股价上涨了 29.4%。</p>
<p>寻找更多最新股市新闻的投资者们请继续关注！</p>
<p>我们将为投资者提供有关周二需了解的所有最热门股市新闻！一些例子包括今天 <strong>特斯拉</strong>（纳斯达克股票代码：<strong>TSLA</strong>）、<strong>达美航空</strong>（纽约证券交易所股票代码：<strong>DAL</strong>）和 <strong>SoFi</strong>（纳斯达克股票代码：<strong>SOFI</strong>）股票的最新动态。所有这些新闻都可以通过以下链接查看！</p>
<h2>周二更多股市新闻</h2>
<ul>
<li>特斯拉股价下跌，因召回 180 万辆电动汽车涉及引擎盖问题</li>
<li>达美航空股票：达美要求 CrowdStrike 赔偿因故障导致的航班延误</li>
<li>SoFi 股票：SoFi 再次提高盈利预期。发生了什么？</li>
</ul>
<p>_<strong>关于低价股和低交易量股票：</strong> 除了极少数例外，InvestorPlace 不会发表关于市值低于 1 亿美元或每日交易量低于 10 万股的公司的评论。这是因为这些 “低价股” 经常成为骗子和市场操纵者的活动场所。如果我们确实发表了可能受到我们评论影响的低交易量股票的评论，我们要求 InvestorPlace.com 的撰稿人披露这一事实，并警告读者存在的风险。</p>
<p><em><strong>阅读更多：</strong> 低价股 —</em> <em>如何获利而不受骗</em></p>
<p><em>在本文发布日期，William White 对本文提及的证券没有（直接或间接）任何持仓。本文中表达的观点属于作者个人，受 InvestorPlace.com</em> <em>发布准则</em> <em>约束。</em></p>

PCSA

<p>Processa Pharmaceuticals（纳斯达克股票代码：PCSA）股价上涨了 29.4%，原因是获得了美国食品和药物管理局（FDA）对其第二阶段临床试验 Next Generation Capecitabine（NGC-Cap）的许可，该药物用于治疗晚期或转移性乳腺癌。该公司预计本季度开始招募患者。股票交易激增，超过 5100 万股交易，而日均交易量为 9 万股</p>

<p><strong>Processa Pharmaceuticals</strong> (NASDAQ: <strong>PCSA</strong>) stock is rising higher on Tuesday after the company posted an update from the Food and Drug Administration (FDA).</p>
<div class="lb-trans"><p><strong>Processa Pharmaceuticals</strong>（纳斯达克股票代码：<strong>PCSA</strong>）股价在周二上涨，此前公司发布了美国食品药品监督管理局（FDA）的最新消息。</p>
</div><p>The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap). This is the company’s lead product candidate and is designed to treat patients with advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>FDA 已经批准 Processa Pharmaceuticals 进行第二阶段临床试验 Next Generation Capecitabine（NGC-Cap）。这是该公司的主力产品候选药物，旨在治疗晚期或转移性乳腺癌患者。</p>
</div><p>With this approval, Processa Pharmaceuticals is able to move forward with a clinical trial of NGC-Cap. The company says that it expect to start enrolling patients in this study this quarter.</p>
<div class="lb-trans"><p>凭借这一批准，Processa Pharmaceuticals 得以推进 NGC-Cap 的临床试验。该公司表示，他们预计本季度将开始招募参与该研究的患者。</p>
</div><p>David Young, president of research and development at Processa Pharmaceuticals, said this about NGC-Cap.</p>
<blockquote>
</blockquote>
<div class="lb-trans"><p>Processa Pharmaceuticals 研发总裁 David Young 对 NGC-Cap 发表了如下看法。</p>
</div><p>“We previously demonstrated in our Phase 1b study that NGC-Cap is more potent than monotherapy capecitabine, providing up to 5-10 times more 5-fluorouracil exposure to cancer cells. This greater exposure resulted in a greater efficacy, with a safety profile better or similar to existing monotherapy with capecitabine.”</p>
<div class="lb-trans"><p>“我们先前在第 1b 阶段研究中证明，NGC-Cap 比单药卡培他滨更有效，使癌细胞暴露于 5-氟尿嘧啶的浓度提高了 5-10 倍。这种更高的暴露导致了更高的疗效，同时安全性优于或类似于现有的单药卡培他滨。”</p>
</div><h2>PCSA Stock Movement Today</h2>
<div class="lb-trans"><h2>今日 PCSA 股票走势</h2>
</div><p>With all of this comes heavy trading of PCSA stock today. That has more than 51 million shares changing hands as of this writing. This is a massive surge compared to the company’s daily average trading volume of about 90,000 shares.</p>
<div class="lb-trans"><p>随着这一消息的传出，PCSA 股票今天交投活跃。截至目前，成交量已超过 5100 万股。与该公司日均成交量约为 9 万股相比，这是一次巨大的涨势。</p>
</div><p>PCSA stock is up 29.4% as of Tuesday morning.</p>
<div class="lb-trans"><p>截至周二上午，PCSA 股价上涨了 29.4%。</p>
</div><p>Investors seeking out even more of the most recent stock market stories are going to want to stick around!</p>
<div class="lb-trans"><p>寻找更多最新股市新闻的投资者们请继续关注！</p>
</div><p>We are offering up insight into all of the hottest stock market news that investors need to know about on Tuesday! A few examples include what’s happening with shares of <strong>Tesla</strong>(NASDAQ: <strong>TSLA</strong>), <strong>Delta</strong> (NYSE: <strong>DAL</strong>) and <strong>SoFi</strong> (NASDAQ: <strong>SOFI</strong>) stock today. All of that news is ready to go at the links below!</p>
<div class="lb-trans"><p>我们将为投资者提供有关周二需了解的所有最热门股市新闻！一些例子包括今天 <strong>特斯拉</strong>（纳斯达克股票代码：<strong>TSLA</strong>）、<strong>达美航空</strong>（纽约证券交易所股票代码：<strong>DAL</strong>）和 <strong>SoFi</strong>（纳斯达克股票代码：<strong>SOFI</strong>）股票的最新动态。所有这些新闻都可以通过以下链接查看！</p>
</div><h2>More Stock Market News for Tuesday</h2>
<ul>
<li>TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</li>
<li>DAL Stock: Delta Wants CrowdStrike to Pay Up for Flight Delays Caused by Outage</li>
<li>SOFI Stock: SoFi Just Raised Its Profit Guidance Again. What’s Going On?</li>
</ul>
<div class="lb-trans"><h2>周二更多股市新闻</h2>
<ul>
<li>特斯拉股价下跌，因召回 180 万辆电动汽车涉及引擎盖问题</li>
<li>达美航空股票：达美要求 CrowdStrike 赔偿因故障导致的航班延误</li>
<li>SoFi 股票：SoFi 再次提高盈利预期。发生了什么？</li>
</ul>
</div><p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong> With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.</em></p>
<div class="lb-trans"><p>_<strong>关于低价股和低交易量股票：</strong> 除了极少数例外，InvestorPlace 不会发表关于市值低于 1 亿美元或每日交易量低于 10 万股的公司的评论。这是因为这些 “低价股” 经常成为骗子和市场操纵者的活动场所。如果我们确实发表了可能受到我们评论影响的低交易量股票的评论，我们要求 InvestorPlace.com 的撰稿人披露这一事实，并警告读者存在的风险。</p>
</div><p><em><strong>Read More:</strong> Penny Stocks —</em> <em>How to Profit Without Getting Scammed</em></p>
<div class="lb-trans"><p><em><strong>阅读更多：</strong> 低价股 —</em> <em>如何获利而不受骗</em></p>
</div><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p><em>在本文发布日期，William White 对本文提及的证券没有（直接或间接）任何持仓。本文中表达的观点属于作者个人，受 InvestorPlace.com</em> <em>发布准则</em> <em>约束。</em></p>
</div>

为什么 Processa Pharmaceuticals（PCSA）的股票今天上涨了 29%？